# Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

> **NCT04417257** · PHASE2,PHASE3 · TERMINATED · sponsor: **Laurent Pharmaceuticals Inc.** · enrollment: 351 (actual)

## Conditions studied

- COVID-19 Disease

## Interventions

- **DRUG:** LAU-7b
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT04417257
- **Lead sponsor:** Laurent Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-18
- **Primary completion:** 2024-02-15
- **Final completion:** 2024-05-30
- **Target enrollment:** 351 (ACTUAL)
- **Why stopped:** Phase 2 completed normally, Phase 3 terminated for futility due to lack of aggravation events.
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417257, "Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04417257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*